Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:57:40.272Z.
Consensus retrieved: 2026-10-06T14:33:11.395Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:57:40.272Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1bedec3c82b29a146d7673ff9ad1d122c49f5fbab6a9d52b7884226ded119d4d
Forward PE Ratio (N/A) = Dated Quote Price ($11.32) / Consensus Forward EPS ($-0.73)
FORWARD PE RATIO
N/A
Novavax, Inc.
Market Cap
$1.86B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Novavax, Inc. (NVAX) | $1.86B | N/A |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | N/A |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.35 |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | N/A |
| Zymeworks Inc. (ZYME)vs › | $1.89B | 24.73 |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 26.47 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | N/A |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | 5.38 |
| Azenta, Inc. (AZTA)vs › | $1.81B | 79.23 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $11.32, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.73 | $-1.54 – $0.76 | 7 | n/m |
| 2027-12-31 | $-0.15 | $-0.78 – $0.91 | 7 | n/m |
| 2028-12-31 | $0.25 | $-0.47 – $1.02 | 6 | 44.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
